NAD+ — NAD+ precursor / sirtuin activator / PARP substrate

NAD+ supplementation is the most debated longevity intervention due to its 'upstream' metabolic role. The key clinical choice is between IV NAD+, oral NR, and oral NMN. IV NAD+ provides the fastest elevation and is preferred in recovery/addiction settings but requires 2-4 hours to manage infusion-related side effects (chest pressure, flushing). Oral NR (Nicotinamide Riboside) has the most human safety data and GRAS status. Oral NMN (Nicotinamide Mononucleotide) is favored by some researchers for a more direct conversion to NAD+ and potential specific transporters. Methylation depletion is a genuine clinical concern — if high-dose precursors are used long-term, adding a methyl donor (TMG 500-1000mg or methyl-B12) is prudent to avoid homocysteine elevation. The cancer risk remains purely theoretical and preclinical; no human trial has demonstrated tumor promotion, but caution is warranted in patients with active malignancy.

Overview

This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.

Compound Class

NAD+ precursor / sirtuin activator / PARP substrate

Mechanism of Action

NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme in all living cells with two primary roles: (1) Electron carrier in metabolic redox reactions (glycolysis, TCA cycle, oxidative phosphorylation — as NAD+/NADH pair); (2) Substrate for sirtuins (SIRT1-7), PARPs, and CD38 — enzymes that regulate DNA repair, epigenetic modification, circadian rhythm, inflammation, and mitochondrial biogenesis. NAD+ levels decline ~50% between age 40-60 via: decreased biosynthesis, increased PARP activity (DNA damage), and increased CD38 expression. NMN and NR are the two commercially viable oral precursors: NR → NMN → NAD+ (intracellular synthesis via Nampt enzyme). NMN may take a more direct route via a recently discovered intestinal transporter (Slc12a8). Key effectors: SIRT1 activates PGC-1α (mitochondrial biogenesis), FOXO3a (stress resistance), p53 (DNA repair); SIRT3 protects mitochondrial integrity; SIRT6 repairs DNA double-strand breaks. IV NAD+ (NAD+ direct infusion, not precursor) achieves higher and faster plasma levels than oral precursors.

Regulatory Status

Dietary supplements (NMN status currently in flux with FDA — FDA previously determined NMN is an investigational drug, not a supplement, but enforcement is stayed); NR is FDA GRAS (Generally Recognized As Safe)

Evidence Level

Moderate — High for metabolic redox roles; Moderate for oral supplementation efficacy (extensive animal data; multiple small human RCTs showing NR/NMN increases NAD+ levels; limited data on hard clinical endpoints in humans); B-grade